Leqvio (Inclisiran) Cost in New Mexico 2026

What Does Leqvio Actually Cost in New Mexico in 2026?

The Novartis wholesale acquisition cost for Leqvio in 2026 is $540 per month, which translates to roughly $3,240 for each six-month injection after the loading period. Cash-pay patients at New Mexico retail pharmacies face the same figure. That number, however, is rarely what commercially insured patients pay after applying the Novartis Leqvio savings card or negotiated plan benefits.

Leqvio (inclisiran) is a small interfering RNA (siRNA) that targets PCSK9 messenger RNA in the liver, blocking synthesis of the PCSK9 protein rather than the protein itself [1]. The FDA approved inclisiran in December 2021 for adults with established atherosclerotic cardiovascular disease (ASCVD) or heterozygous familial hypercholesterolemia (HeFH) who require additional LDL-C lowering on top of maximally tolerated statins [2]. Because the drug is given twice yearly after two loading doses, the annualized cost is approximately $6,480 at list price before any rebates or discounts.

For context, the ACC/AHA 2018 cholesterol guidelines recommend adding a PCSK9 inhibitor or inclisiran when LDL-C remains above 70 mg/dL despite high-intensity statin therapy in patients with ASCVD [3]. New Mexico has higher-than-average rates of cardiovascular disease mortality, making access to LDL-lowering therapies a significant public health concern [4].

The honest bottom line: most commercially insured New Mexico patients will pay somewhere between $0 and a few hundred dollars per injection with assistance programs. Medicaid enrollees currently have no covered path to brand Leqvio. Uninsured patients face the full $540/month list price unless they access compounded inclisiran or qualify for patient assistance.

Does New Mexico Medicaid Cover Leqvio?

New Mexico Medicaid does not cover Leqvio as of 2026. The Centennial Care program, which administers Medicaid managed care in New Mexico through contractors including Blue Cross Blue Shield of New Mexico, Presbyterian Health Plan, and UnitedHealthcare Community Plan, has not added inclisiran to its preferred drug list [5]. Prior authorization requests for Leqvio through Medicaid have a high denial rate statewide because the program cites the availability of generic statins and ezetimibe as therapeutically sufficient alternatives.

The Centers for Medicare and Medicaid Services (CMS) has noted that PCSK9 inhibitors and inclisiran face significant formulary barriers across state Medicaid programs nationally [6]. New Mexico follows that national pattern.

Patients enrolled in Medicare Part D may have better access. Some Part D plans in New Mexico do include Leqvio on their formulary at Tier 3 or Tier 4, meaning a cost-sharing amount of $100 to $400 per injection after meeting the deductible. Patients who reach the Medicare catastrophic coverage threshold will see out-of-pocket costs drop substantially for the remainder of the plan year. Checking the Medicare Plan Finder at medicare.gov is the most reliable way to compare Part D plan formularies before enrollment or during open enrollment each October through December.

For Medicaid beneficiaries who are denied Leqvio, the clinical alternative pathway involves maximizing statin dose, adding ezetimibe 10 mg daily (which lowers LDL-C an additional 18 to 20 percent), and considering PCSK9 inhibitor monoclonal antibodies such as evolocumab (Repatha) or alirocumab (Praluent), which have distinct formulary status and may be covered in some Centennial Care plans [7].

Which Commercial Insurance Plans Cover Leqvio in New Mexico?

Coverage varies by plan, but the trend in 2026 is toward broader formulary inclusion for inclisiran compared with 2022 and 2023.

Large commercial plans operating in New Mexico, including Presbyterian Health Plan commercial, Blue Cross Blue Shield of New Mexico (Regence affiliate), and UnitedHealthcare commercial, generally include Leqvio at Tier 3 or Tier 4 with prior authorization requirements. The typical prior authorization criteria mirror the FDA label: documented ASCVD or HeFH, LDL-C above 70 mg/dL (or 100 mg/dL depending on plan), and evidence of maximally tolerated statin therapy for at least 90 days [8].

Employer self-insured plans in New Mexico follow their pharmacy benefit manager (PBM) formularies, most of which are managed by CVS Caremark, Express Scripts, or OptumRx. Each PBM negotiates rebates with Novartis independently, so out-of-pocket costs differ even within the same employer tier.

The 2023 ORION-10 and ORION-11 pooled analysis published in NEJM confirmed that inclisiran 284 mg subcutaneous injection reduced LDL-C by 49.9 percent compared with placebo at day 510 in patients on statins, with a consistent safety profile [9]. Payers increasingly cite this data when justifying formulary inclusion, particularly for high-risk ASCVD patients.

Patients appealing a denial should reference the AHA/ACC 2022 guideline on nonstatin therapies, which states: "For very high-risk patients who require additional LDL-C lowering, PCSK9 inhibitors and inclisiran are reasonable options when LDL-C remains above 70 mg/dL on maximally tolerated statin plus ezetimibe therapy" [10]. A written letter from the prescribing cardiologist or primary care physician that directly quotes guideline language significantly strengthens an appeal.

How Does the Novartis Leqvio Savings Card Work in New Mexico?

The Novartis patient savings program for Leqvio allows eligible commercially insured patients in New Mexico to pay as little as $0 per dose. Patients must not be enrolled in a government-funded program such as Medicare, Medicaid, CHIP, TRICARE, or any state pharmaceutical assistance program to qualify [11].

Enrollment is online through the Novartis patient services portal. After enrollment, the savings card applies at participating specialty pharmacies. Because Leqvio is a specialty injectable, it is almost always dispensed through a specialty pharmacy rather than a retail chain. Specialty pharmacies that operate in New Mexico and dispense Leqvio include Accredo (an Express Scripts company), Biologics by McKesson, and several hospital outpatient pharmacy programs affiliated with Presbyterian Healthcare Services and UNM Health.

The savings card covers the gap between the plan's negotiated rate and the patient's cost-sharing obligation, up to the program's annual maximum benefit. Novartis has historically set that maximum at $6,000 to $10,000 per year, though the exact cap is subject to change and patients should verify current terms at the time of enrollment [12].

Patients who lose commercial insurance coverage, transition to Medicaid, or turn 65 and enroll in Medicare must immediately notify the program, as continuing to use the savings card while enrolled in a government program is a federal compliance violation.

Is Compounded Inclisiran Legal in New Mexico?

Compounded inclisiran from a 503A pharmacy is legal in New Mexico. Under Section 503A of the Federal Food, Drug, and Cosmetic Act, licensed compounding pharmacies may prepare inclisiran for individual patients based on a valid prescription from a licensed prescriber, provided the drug is not on the FDA's list of drugs withdrawn for safety or efficacy reasons and other statutory conditions are met [13].

New Mexico does not impose additional state-level restrictions beyond federal 503A requirements that would specifically prohibit inclisiran compounding. The New Mexico Board of Pharmacy regulates 503A compounders in the state and requires compliance with USP <797> standards for sterile preparations, since inclisiran is administered as a subcutaneous injection [14].

The practical cost difference is significant. While the Novartis brand costs $540 per month at list price, compounded inclisiran from a licensed 503A pharmacy may be available for considerably less, with some telehealth platforms quoting prices in the range of $80 to $200 per month depending on dose and supplier. These prices are not guaranteed and will vary by pharmacy.

Important caveats apply. Compounded drugs are not FDA-approved. The FDA does not verify the potency, sterility, or bioequivalence of compounded inclisiran against the brand product. Patients choosing compounded inclisiran should confirm that the pharmacy holds a valid 503A license, follows USP <797> sterile compounding standards, and uses active pharmaceutical ingredient (API) from an FDA-registered supplier [15]. The FDA's database of registered human drug compounders is publicly searchable at fda.gov [16].

Prescribers in New Mexico may write a prescription for compounded inclisiran when the patient has a documented medical need and the clinical decision is documented in the chart. No New Mexico statute currently bars a licensed physician, PA, or NP from prescribing compounded inclisiran off-label.

Can You Get Leqvio via Telehealth in New Mexico?

Telehealth prescribing of Leqvio is legal in New Mexico. The state allows prescribing via synchronous audio-video telehealth encounters, provided the prescriber holds a valid New Mexico license (or qualifies under a reciprocity or special telehealth license) and meets the standard of care for establishing a patient-prescriber relationship [17].

New Mexico Senate Bill 317, signed into law in 2021, expanded telehealth prescribing authority broadly and removed several pre-pandemic restrictions on establishing new patient relationships via video. The New Mexico Medical Board's telehealth rules require audio-video (not audio-only) for new controlled substance prescriptions, but inclisiran is not a controlled substance, so audio-only visits may satisfy prescribing requirements in some circumstances, though audio-video remains best practice [18].

After a telehealth prescribing visit, the injection itself must still be administered by a healthcare professional. Leqvio is not approved for self-administration. In New Mexico, patients typically receive the injection at a physician's office, cardiology clinic, or in some cases a retail health clinic. Some integrated health systems such as UNM Health and Presbyterian allow injection scheduling through their patient portal after a telehealth consultation establishes the prescription.

HealthRX clinicians licensed in New Mexico can evaluate lipid panels, review statin history, and prescribe inclisiran (brand or compounded) via telehealth visits. Patients should bring a fasting lipid panel drawn within the past 90 days and a list of current medications to the visit.

What Do the Clinical Trials Say About Inclisiran Efficacy?

The ORION-10 trial (N=1,561, patients with ASCVD) and ORION-11 trial (N=1,617, patients with ASCVD or ASCVD risk equivalents including HeFH) form the primary evidence base for the FDA approval. Both trials were published in the New England Journal of Medicine in March 2020 [9].

In ORION-10, inclisiran 284 mg subcutaneous injection reduced LDL-C by 52.3 percent vs. placebo at day 510 (P<0.001). In ORION-11, the reduction was 49.9 percent vs. placebo at day 510 (P<0.001). Both trials used a dosing schedule of day 1, day 90, then every six months, which is the approved commercial schedule [9].

The ORION-4 trial, a large cardiovascular outcomes study enrolling more than 15,000 patients, is ongoing. Interim safety data have not revealed new safety signals beyond injection-site reactions, which occurred in approximately 2.6 percent of inclisiran patients vs. 0.9 percent placebo [9].

The European Society of Cardiology 2021 guidelines on dyslipidaemia (joint ESC/EAS) state: "Inclisiran may be considered for patients who do not reach LDL-C goals on maximally tolerated statin plus ezetimibe, as an alternative to PCSK9 inhibitor monoclonal antibodies, with the advantage of twice-yearly dosing improving adherence" [20]. Twice-yearly dosing is clinically meaningful in populations with medication adherence challenges, a documented issue in cardiovascular disease management [21].

The Cheapest Way to Get Leqvio in New Mexico: A Decision Path

Cost minimization for New Mexico patients follows a clear sequence based on insurance status.

Commercially insured patients should first check whether their plan covers Leqvio and, if so, enroll in the Novartis savings card to reduce out-of-pocket cost toward $0. If the plan excludes Leqvio, filing a prior authorization with guideline citations and a cardiologist letter is the next step. Denial appeals succeed at a meaningful rate when supported by documented ASCVD and prior statin failure [22].

Medicare Part D patients should compare New Mexico-available Part D plans during open enrollment specifically for inclisiran formulary status. Moving to a plan that covers Leqvio at Tier 3 may cost less annually than paying out of pocket even with higher premiums. The Medicare Extra Help (Low Income Subsidy) program can further reduce cost-sharing for qualifying patients [23].

Uninsured patients or Medicaid patients face the starkest cost barrier for brand Leqvio. The Novartis Patient Assistance Program (PAP) offers free drug to patients who meet income criteria, typically below 400 percent of the federal poverty level and without insurance coverage. Applications are submitted through the Novartis patient services portal [24]. Compounded inclisiran through a licensed New Mexico 503A pharmacy or a telehealth platform operating in-state represents the most accessible low-cost option for patients who do not qualify for PAP or are waiting for PAP approval.

A fasting LDL-C above 70 mg/dL on high-intensity statin therapy, documented in a chart note, is the minimum clinical bar that justifies pursuing inclisiran by any pathway. Patients whose LDL-C is controlled on generic rosuvastatin 20 to 40 mg daily do not have a clinical indication for inclisiran, regardless of cost.

Injection Administration in New Mexico: Where to Go

Leqvio is administered as a subcutaneous injection in the abdomen, upper arm, or thigh by a healthcare professional. It cannot be dispensed to patients for home administration. This means every injection requires a clinical visit, which creates an indirect cost (time, travel, copay) beyond the drug price itself.

In Albuquerque, cardiology practices affiliated with Presbyterian Heart and Vascular Institute and UNM Cardiology both stock Leqvio through buy-and-bill arrangements with Novartis, meaning the drug is purchased by the practice and billed directly to the patient's medical benefit (not pharmacy benefit) [25]. This distinction matters: medical benefit cost-sharing is often different from pharmacy benefit cost-sharing, and some patients pay less when Leqvio is billed under the medical benefit.

In rural New Mexico, access to injection administration is a real barrier. Telehealth prescribing paired with injection at a federally qualified health center (FQHC) or rural health clinic is the most practical model. New Mexico has 26 FQHCs, including sites in Las Cruces, Roswell, Farmington, and Gallup [26]. Patients should call ahead to confirm whether the FQHC stocks Leqvio or can arrange buy-and-bill.

LDL-C Targets and Monitoring After Starting Inclisiran

The ACC/AHA 2018 guidelines recommend an LDL-C target below 70 mg/dL for very high-risk ASCVD patients and below 55 mg/dL for patients with multiple major ASCVD events [3]. Inclisiran's 50 percent LDL-C reduction makes it capable of moving most patients from the 100 to 140 mg/dL range down to the 50 to 70 mg/dL range [9].

After starting inclisiran, a lipid panel should be drawn at approximately day 90 (around the time of the second loading dose) to confirm response. Subsequent lipid panels every six to twelve months align with the dosing schedule and allow the prescriber to assess whether LDL-C targets are being met [27]. No dose adjustment exists for inclisiran; the approved dose is 284 mg regardless of LDL-C response. If the patient does not respond, adherence should be assessed and alternative mechanisms such as familial hypercholesterolemia homozygous (HoFH) genotype should be considered, as inclisiran is not approved for HoFH [2].

Liver function tests are not routinely required before or during inclisiran therapy based on the ORION trial safety data, though patients with known significant hepatic impairment should be evaluated individually [28]. Renal impairment does not require dose adjustment.

Frequently Asked Questions